Early Detriment Analysis of First-Line Nivolumab plus Ipilimumab-Based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer.

Saved in:
Bibliographic Details
Title: Early Detriment Analysis of First-Line Nivolumab plus Ipilimumab-Based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer.
Authors: Borghaei H; Hematology and Oncology Department, Fox Chase Cancer Center, Temple Health, Philadelphia, Pennsylvania., Balli D; Informatics and Predictive Sciences, Bristol Myers Squibb, Princeton, New Jersey., Paz-Ares LG; Medical Oncology Department, Hospital Universitario 12 de Octubre, Universidad Complutense de Madrid, Madrid, Spain., Reck M; Department of Thoracic Oncology, Airway Research Center North, German Center for Lung Research, LungenClinic Grosshansdorf, Grosshansdorf, Germany., Lu S; Department of Medical Oncology, Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China., Ramalingam SS; Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia., Brahmer JR; Department of Oncology, The Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Kimmel Cancer Center, Baltimore, Maryland., John T; Medical Oncology Department, Austin Hospital, Heidelberg, Australia., Carbone DP; Department of Medical Oncology, The Ohio State University Comprehensive Cancer Center and the Pelotonia Institute for Immuno-Oncology, Columbus, Ohio., Ciuleanu TE; Department of Medical Oncology, Institutul Oncologic Prof. Dr. Ion Chiricuta, University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania., Schenker M; Department of Medical Oncology, Sf Nectarie Oncology Center, University of Medicine and Pharmacy of Craiova, Craiova, Romania., Cobo M; Department of Medical Oncology, Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen de la Victoria, Malaga, Spain., Zurawski B; Chemotherapy Department, Ambulatorium Chemioterapii, Bydgoszcz, Poland., Pluzanski A; Department of Lung Cancer and Chest Tumours, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland., Lee JS; Department of Hematology/Oncology, Seoul National University Bundang Hospital, Seongnam, Republic of Korea., Agrawal S; Global Drug Development, Bristol Myers Squibb, Princeton, New Jersey., Spires T; Translational Medicine, Bristol Myers Squibb, Princeton, New Jersey., Neely J; Translational Medicine, Bristol Myers Squibb, Princeton, New Jersey., Ip V; Global Medical Oncology, Bristol Myers Squibb, Princeton, New Jersey., Eccles LJ; Global Medical Oncology, Bristol Myers Squibb, Princeton, New Jersey., Chang H; Informatics and Predictive Sciences, Bristol Myers Squibb, Princeton, New Jersey., Szustakowski JD; Translational Bioinformatics, Bristol Myers Squibb, Princeton, New Jersey., Bhatia S; Global Medical Oncology, Bristol Myers Squibb, Princeton, New Jersey., Yadav A; Data Science, Bristol Myers Squibb, Princeton, New Jersey., Eddy N; Data Science, Bristol Myers Squibb, Princeton, New Jersey., Geese WJ; Translational Medicine, Bristol Myers Squibb, Princeton, New Jersey., O'Byrne KJ; Department of Medical Oncology, Princess Alexandra Hospital, Translational Research Institute and Queensland University of Technology, Brisbane, Australia.
Source: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2026 Jun 26, pp. OF1-OF14. Date of Electronic Publication: 2026 Jun 26.
Publication Type: Journal Article
Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1557-3265
DOI:10.1158/1078-0432.CCR-25-0942